Omnicell, Inc. to Post Q3 2024 Earnings of $0.15 Per Share, Zacks Research Forecasts (NASDAQ:OMCL)

Omnicell, Inc. (NASDAQ:OMCL) – Equities research analysts at Zacks Research boosted their Q3 2024 earnings per share (EPS) estimates for Omnicell in a research note issued on Tuesday, May 21st. Zacks Research analyst U. Biswas now expects that the company will earn $0.15 per share for the quarter, up from their previous estimate of $0.11. The consensus estimate for Omnicell’s current full-year earnings is $0.16 per share. Zacks Research also issued estimates for Omnicell’s Q4 2024 earnings at $0.23 EPS, FY2024 earnings at $0.20 EPS, Q1 2025 earnings at $0.10 EPS, Q2 2025 earnings at $0.14 EPS, Q3 2025 earnings at $0.12 EPS, Q4 2025 earnings at $0.15 EPS, FY2025 earnings at $0.51 EPS, Q1 2026 earnings at $0.22 EPS and FY2026 earnings at $0.56 EPS.

Other equities analysts also recently issued research reports about the stock. Wells Fargo & Company reduced their target price on shares of Omnicell from $28.00 to $26.00 and set an “equal weight” rating for the company in a research note on Friday, February 9th. Benchmark reiterated a “buy” rating and issued a $38.00 price objective on shares of Omnicell in a research note on Tuesday, April 30th. One research analyst has rated the stock with a sell rating, three have given a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, Omnicell has an average rating of “Hold” and a consensus price target of $42.20.

Omnicell Trading Down 1.7 %

Shares of Omnicell stock opened at $31.70 on Thursday. The stock has a market capitalization of $1.46 billion, a P/E ratio of -68.91, a P/E/G ratio of 144.45 and a beta of 0.77. Omnicell has a 52-week low of $25.69 and a 52-week high of $77.14. The company has a debt-to-equity ratio of 0.48, a quick ratio of 2.13 and a current ratio of 2.38. The stock’s 50-day simple moving average is $28.67 and its 200 day simple moving average is $31.24.

Omnicell (NASDAQ:OMCL) last issued its earnings results on Thursday, May 2nd. The company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $0.17. The firm had revenue of $246.15 million for the quarter, compared to analyst estimates of $235.70 million. Omnicell had a positive return on equity of 2.41% and a negative net margin of 1.91%.

Institutional Investors Weigh In On Omnicell

A number of institutional investors and hedge funds have recently modified their holdings of OMCL. Covestor Ltd boosted its stake in Omnicell by 65.6% during the third quarter. Covestor Ltd now owns 1,355 shares of the company’s stock valued at $61,000 after buying an additional 537 shares during the period. Acadian Asset Management LLC bought a new stake in shares of Omnicell during the 3rd quarter valued at about $62,000. EntryPoint Capital LLC grew its holdings in shares of Omnicell by 121.2% during the first quarter. EntryPoint Capital LLC now owns 2,455 shares of the company’s stock worth $72,000 after purchasing an additional 1,345 shares in the last quarter. Neo Ivy Capital Management bought a new position in shares of Omnicell in the third quarter worth approximately $78,000. Finally, Benjamin Edwards Inc. raised its stake in Omnicell by 36.4% in the first quarter. Benjamin Edwards Inc. now owns 3,253 shares of the company’s stock valued at $95,000 after purchasing an additional 868 shares in the last quarter. 97.70% of the stock is owned by hedge funds and other institutional investors.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.